ORAMED PHARMACEUTICALS INC.

For the period ended Dec 31, 2025. Filed Mar 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 26, 2026

ORMP$3.97-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

**CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands

Year ended December 31, · Year ended December 31,
2025 · 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)		$64,016	$(19,103)
Adjustments required to reconcile net income (loss) to net cash used in operating activities:
Depreciation		121	193
Exchange differences and interest on deposits		830	(2,700)
Changes in fair value of investments		(86,096)	7,413
Stock-based compensation		5,992	4,053
Gain on amounts funded in respect of employee rights upon retirement		(12)	(5)
Change in accrued interest on short-term borrowings		-	(1,463)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(998)	(356)
Accounts payable, accrued expenses and related parties		1,130	3,525
Net changes in operating lease		117	43
Deferred revenues		(2,000)	-
Deferred income		(105)	-
Liability for employee rights upon retirement		9	2
Deferred tax liabilities		7,911	-
Other liabilities		(60)	(14)
Total net cash used in operating activities		(9,145)	(8,412)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(9)	(18)
Purchase of short-term deposits		(10,948)	(54,450)
Purchase of marketable securities		(9,846)	-
Investments at fair value		(64,712)	(1,307)
Purchase of convertible note		(3,000)	-
Proceeds from redemption of short-term deposits		54,450	97,152
Exercise of Closing Penny Warrants and Subsequent Penny Warrants		-	(65)
Proceeds from loan to an equity method investee		6,251	-
Loan to investment in equity method		(7,000)	-
Real estate investment		(1,924)	-
Equity method investee		(250)	-
Proceeds from long-term deposits		-	5
Proceeds from marketable securities		2,865	-
Proceeds from long-term investments		39,566	64,500
Total net cash provided by investing activities		5,443	105,817
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchase and retirement of common stock		(4,741)	(2,484)
Loans repaid		-	(49,550)
Tax withholdings related to stock-based compensation settlements		-	(2)
Total net cash used in financing activities		(4,741)	(52,036)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		(30)	(4)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(8,473)	45,365
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		54,420	9,055
CASH AND CASH EQUIVALENTS AT END OF YEAR		$45,947	$54,420
(A) SUPPLEMENTARY DISCLOSURE ON CASH FLOWS:
Interest paid	$	-	$2,316
Interest received		$4,626	$7,376
(B) SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
2024 Refinancing Tranche A		-	(21,575)
2024 Refinancing Tranche B		-	25,000
Excise tax for repurchase and retirement of common stock		(15)	(10)
Recognition of operating lease right-of-use assets and liabilities		600	58
Waiver of loan granted to subsidiary		952	-
Derecognition of right-of-use asset		-	(26)
Derecognition of lease liability		-	23
Purchases of marketable securities not yet settled		254	-
Dividends declared but not yet paid in cash		10,870	-
Warrants received from Alpha Tau		2,727	-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.